` Comparison: PRL vs NOVN - Alpha Spread

P
PRL
vs
NOVN

Over the past 12 months, PRL has underperformed NOVN, delivering a return of 0% compared to the NOVN's +32% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
PRL
NOVN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

P
PRL Intrinsic Value
Not Available
NOVN Intrinsic Value
107.11 CHF
Overvaluation 18%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
P
Pierrel SpA
MIL:PRL
1.745 EUR
Novartis AG
SIX:NOVN
130.16 CHF
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
PRL, NOVN

PRL
NOVN
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
P
Pierrel SpA
Revenue
Novartis AG
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
PRL, NOVN

PRL
NOVN
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
P
Pierrel SpA
MIL:PRL
Novartis AG
SIX:NOVN
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

PRL
70.5%
NOVN
75.8%
LTM 3Y Avg 5Y Avg 10Y Avg
P
Pierrel SpA
Novartis AG

Operating Margin

PRL
10.7%
NOVN
33.2%
LTM 3Y Avg 5Y Avg 10Y Avg
P
Pierrel SpA
Novartis AG

Net Margin

PRL
9.5%
NOVN
24.8%
LTM 3Y Avg 5Y Avg 10Y Avg
P
Pierrel SpA
Novartis AG

FCF Margin

PRL
-10%
NOVN
27.1%
LTM 3Y Avg 5Y Avg 10Y Avg
P
Pierrel SpA
Novartis AG

ROE

PRL
14.4%
NOVN
31%
LTM 3Y Avg 5Y Avg 10Y Avg
P
Pierrel SpA
Novartis AG

ROA

PRL
5%
NOVN
13.1%
LTM 3Y Avg 5Y Avg 10Y Avg
P
Pierrel SpA
Novartis AG

ROIC

PRL
6.5%
NOVN
17.8%
LTM 3Y Avg 5Y Avg 10Y Avg
P
Pierrel SpA
Novartis AG

ROCE

PRL
7.6%
NOVN
23.8%
LTM 3Y Avg 5Y Avg 10Y Avg
P
Pierrel SpA
Novartis AG

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
PRL, NOVN

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PRL, NOVN

Loading
PRL
NOVN
Difference
www.alphaspread.com

Performance By Year
PRL, NOVN

Loading
PRL
NOVN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare PRL to other stocks
LLY
Eli Lilly and Co
Cheaper
vs PRL
JNJ
Johnson & Johnson
Cheaper
vs PRL
ROG
Roche Holding AG
Cheaper
vs PRL
AZN
AstraZeneca PLC
Cheaper
vs PRL
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett